A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adults With NASH and T2DM
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs HTD 1801 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors HighTide Biopharma
- 23 Oct 2019 Planned End Date changed from 31 Oct 2019 to 5 Mar 2020.
- 23 Oct 2019 Planned primary completion date changed from 30 Sep 2019 to 4 Feb 2020.
- 22 Oct 2019 According to a HighTide Biopharma media release, this study results are expected in early 2020.